Biopharma Development in China and International Cooperation
Wednesday, October 12, 10:30am - 11:45am
China is one of the world's fastest growing emerging pharmaceutical markets. With its international position and influence on the rise, it has attracted a growing number of multinational pharmaceutical companies and research institutions to the country. An international cooperation has emerged between China and the worldwide bio-pharmaceutical industry, creating great opportunities, and challenges to be explored.
As such, the bio-pharmaceutical industry has been positioned as one of the national strategic and emerging industries, and the Chinese government is paying great attention to its developments. The government has established funds for research and development, aiming to give special support to the enterprises focused on innovation and participation in international cooperation; and to promote the bio-pharmaceutical industry with rapid and healthy development.
Zhangjiang Hi-Tech Park is one of the earliest National Hi-Tech Parks with the leading bio-pharmaceutical industry as its major industry. With Zhangjiang hosting dual development opportunities for the international and local bio-pharmaceutical industries, the concept of "innovation and integration" will positively undertake and promote the bio-pharmaceutical industry.
During this session, we will share the national strategic planning for the Chinese bio-pharmaceutical industry, the development of Zhangjiang Bio-Pharmaceutical industry cluster, and successful international case studies from Zhangjiang. We’ll also be exploring how to promote the global bio-pharmaceutical industry through enhanced international cooperation so that it may continue to flourish.
Moderator:
William R. Keller, Vice General Manager, Shanghai Zhangjiang Biotech & Pharmaceutical Base Development Co. Ltd.
Panelists:
- Mr. Yuliang Huang, CEO, Generon (Shanghai) Corporation
- Dr. Douglas Khoo, Corporate VP Operations China & Indonesia, BPE, Boehringer Ingelheim
- Mr. Jun Ren, CEO, Newsummit Biopharma Group
- Richard Wang, Senior Director & Head of Operations, GSK R&D China
- Mr. David Wilkinson, Global Product Director, AstraZeneca R&D Charnwood
- Dr. Yichun Zhu, Dean of College Pharmacy, Institute of Drug R&D, Fudan University
Speech 1： Topic: “The registration and regulatory of China biological products and the overview of China pharmaceutical industry” 15 mins
Mrs He Bai, Division of Biological Products, Department of Drug Registration, SFDA
Speech 2： Topic: Innovation and Integrations-Development Strategy of Zhangjian Pharmaceutical Industry 15 mins
Mr. Lanzhong Wang, General Manager, Shanghai Zhangjiang Biotech & Pharmaceutical Base Development Co. Ltd
Speech 3： Topic: Chance and Challenge for MNEs’ in the area of new drug R&D in China 15 mins
Richard Wang, Senior Director and Head of Operations, GSK R&D China.